defy medical semaglutide SkinnyRx maximus tirzepatide reviews Tribe Weight

In fact, cardiovascular disease represents the leading cause of death for patients with NAFLD.[15], [16] When focussing on liver-related morbidity and mortality, NASH represents the third most common cause of cirrhosis within the United States, but it is predicted to become the leading cause over the next few years.17 NASH cirrhosis is currently the primary aetiology for dual liver-kidney transplantation and is estimated to become the number one indication for liver transplant by 2020.[18], [19], [20] Overall, the distinction between those with NAFLD and those with NASH is clinically relevant given that multiple studies have demonstrated that patients with NASH are at higher risk of adverse liver-related outcomes, with the degree of fibrosis contributing most significantly to this increased risk.[3], [21], [22] The striking prevalence of NAFLD paired with its profound complications underscores the critical need for safe, effective, and broadly applicable therapy

doi: 10.1002/14651858.CD007221.pub2

Lecce E et al

Pick up in-spa, or shipping is an additional $25

Retatrutide is an experimental drug under development for the treatment of obesity and related metabolic disorders, such as type 2 diabetes